Logo
x

Search category

Subscribe Now

P-II

Finch Reports Results of CP101 in P-II PRISM-EXT Trial for the Prevention of Recurrent C. difficile Infection

Finch Reports Results of CP101 in P-II PRISM-EXT Trial for the Prevention of Recurrent C. difficile Infection

  • November 11, 2021
Immunic Reports Completion of Patient Enrollment in P-II CALDOSE-1 Trial of IMU-838 for the Treatment of Ulcerative Colitis

Immunic Reports Completion of Patient Enrollment in P-II CALDOSE-1 Trial of IMU-838 for the Treatment of Ulcerative Colitis

  • October 28, 2021
PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

PharmaTher Initiates P-II KET-LID Study of Ketamine for Levodopa-Induced Dyskinesia in Patients with Parkinson's Disease

  • October 7, 2021
JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 2021

JW Reports One-Year Follow-Up Results of Relmacabtagene Autoleucel in P-II RELIANCE Study for the Treatment of R/R LBCL at CSCO 20...

  • September 27, 2021
Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazil

Sorrento Initiates Enrollment in P-II MSC-COV-202BR Study for the Treatment of Acute Respiratory Distress due to COVID-19 in Brazi...

  • September 7, 2021
AC Immune Report Results of Semorinemab in P-II Lauriet Study for the Treatment of Alzheimer's Disease

AC Immune Report Results of Semorinemab in P-II Lauriet Study for the Treatment of Alzheimer's Disease

  • September 1, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.